Undertaking a transrectal ultrasound guided biopsy of the prostate
Published Dec 2006 | ISBN 978 1 84463 041 7
PDF Format (119Kb)
The Prostate Cancer Risk Management Programme ensures that men requesting a prostate-specific antigen (PSA) test are provided with information about the benefits, limitations and risks to enable them to make an informed choice. The PCRMP is also responsible for improving the quality of PSA testing, for the quality of processes in the diagnosis of prostate cancer and for providing a systematic and standardised follow up pathway as far as the point of diagnosis.
These guidelines for transrectal ultrasound guided biopsy of the prostate were developed in association with the Department of Pathology, University of Liverpool. In addition, a systematic review was commissioned by the Centre for Reviews and Dissemination, University of York, to evaluate systematic prostate biopsy methods in the investigation for prostate cancer.